Abstract
Investigators in Europe and North America have been involved in clinical trials of a new agent for the treatment of relapsed acute myeloid leukemia (AML), gemtuzumab ozogamicin (CMA-676, Mylotarg™). Gemtuzumab ozogamicin is a conjugate of a monoclonal antibody and a potent cytotoxin. It has completed phase II trials and has been approved in the USA for the treatment of patients > 60 years old with AML in first relapse who are not considered candidates for conventional chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Löwenberg B, Downing JR, Burnett A: Acute myeloid leukemia. New Engl J Med 341: 1051 – 1062, 1999
Griffin JD, Linch D, Sabbath K, et al: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8: 521 – 534, 1984
Dinndorf PA, Andrews RG, Benjamin D, et al: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67: 1048 – 1053, 1986
Scheinberg DA, Lovett D, Divgi CR, et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9: 478 – 490, 1991
Appelbaum FR, Matthews DC, Eary JF, et al: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54: 829 – 833, 1992
Zein N, Poncin M, Nilakantan R, et al: Calicheamicin g1l and DNA: molecular recognition process responsible for site-specificity. Science 244: 697 – 699, 1989
Hamann PR, Hinman LM, Hollander IJ, et al: AntiCD33 calicheamicin hybrid conjugates for the treatment of acute myelogenous leukemia. Proceedings of AACR 37:471,1996 (abstr)
Sievers EL, Appelbaum FR, Spielberger RT, et al: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678 – 3684, 1999
Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse. In press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Larson, R.A. (2003). CMA-676: Mechanism of Action and Clinical Results. In: Hiddemann, W., Haferlach, T., Unterhalt, M., Büchner, T., Ritter, J. (eds) Acute Leukemias IX. Haematology and Blood Transfusion Hämatologie und Bluttransfusion, vol 41. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59358-1_28
Download citation
DOI: https://doi.org/10.1007/978-3-642-59358-1_28
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63949-4
Online ISBN: 978-3-642-59358-1
eBook Packages: Springer Book Archive